Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has a beta value of 0 and has seen 2,110,036 shares traded in the last trading session. The company, currently valued at $6.24 Billion, closed the last trade at $45.95 per share which meant it gained $3.38 on the day or 7.94% during that session. The ADPT stock price is -6.64% off its 52-week high price of $49 and 66.94% above the 52-week low of $15.19. If we look at the company’s 10-day average daily trading volume, we find that it stood at 936.18 Million shares traded. The 3-month trading volume is 1.02 Million shares.
The consensus among analysts is that Adaptive Biotechnologies Corporation (ADPT) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 1 out of 7 have rated it as a Hold, with 6 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.28.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) trade information
Sporting 7.94% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Sep 15 when the ADPT stock price touched $46.47- or saw a rise of 1.12%. Year-to-date, Adaptive Biotechnologies Corporation shares have moved 53.58%, while the 5-day performance has seen it change 26.79%. Over the past 30 days, the shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) have changed 16.92%. Short interest in the company has seen 3.04 Million shares shorted with days to cover at 2.98.
Wall Street analysts have a consensus price target for the stock at $51.8, which means that the shares’ value could jump 12.73% from current levels. The projected low price target is $42 while the price target rests at a high of $63. In that case, then, we find that the current price level is +37.11% off the targeted high while a plunge would see the stock lose -8.6% from current levels.
Adaptive Biotechnologies Corporation (ADPT) estimates and forecasts
Figures show that Adaptive Biotechnologies Corporation shares have underperformed across the wider relevant industry. The company’s shares have gained +155.14% over the past 6 months, with this year growth rate of 7.92%, compared to 13.7% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are -154.5% and -52.9% for the next quarter. Revenue growth from the last financial year stood is estimated to be +13%.
Earnings growth for 2020 is a modest -42% while over the next 5 years, the company’s earnings are expected to increase by 3.9%.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s Major holders
Insiders own 5.47% of the company shares, while shares held by institutions stand at 73.44% with a share float percentage of 77.69%. Investors are also buoyed by the number of investors in a company, with Adaptive Biotechnologies Corporation having a total of 197 institutions that hold shares in the company. The top two institutional holders are Viking Global Investors, L.P. with over 33.49 Million shares worth more than $1.62 Billion. As of June 29, 2020, Viking Global Investors, L.P. held 24.67% of shares outstanding.
The other major institutional holder is Matrix Capital Management, with the holding of over 15.12 Million shares as of June 29, 2020. The firm’s total holdings are worth over $731.27 Million and represent 11.13% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund. As of June 29, 2020, the former fund manager holds about 1.47% shares in the company for having 1995951 shares of worth $96.56 Million while later fund manager owns 1.75 Million shares of worth $84.46 Million as of June 29, 2020, which makes it owner of about 1.29% of company’s outstanding stock.